LONDON, Sept. 16, 2025 — Leads & Copy — Causaly has launched Causaly Agentic Research, an agentic AI platform designed for life sciences research and development. The platform offers specialized AI agents that access, analyze, and synthesize biomedical knowledge and competitive intelligence. Scientists can automate complex tasks, scale R&D operations, and discover insights.
Causaly Agentic Research builds on Causaly Deep Research, providing a conversational interface for users to interact with AI research agents. These industry-specific agents combine internal and external data to create a single source of truth for research, completing tasks across drug discovery and development.
According to Yiannis Kiachopoulos, co-founder and CEO of Causaly, agentic AI changes how life sciences conducts research. The AI agents emulate the scientific process, analyzing data and finding biological relationships, allowing scientists to access diverse evidence sources and focus on higher-value work.
Causaly addresses the challenges of manual and siloed processes in research by combining biomedical information with competitive intelligence and proprietary datasets. The platform aims to eliminate silos, improve productivity, and accelerate scientific ideas to market.
Causaly Agentic Research, part of the Causaly platform, provides multiple AI agents that collaborate to conduct complex analysis, verify quality and accuracy, scan the scientific landscape, deliver traceable insights, and connect with internal systems and data sources.
Causaly Agentic Research will be available in October 2025, with additional AI agents planned by the end of the year.
Contact:
Yiannis Kiachopoulos, co-founder and CEO of Causaly.
Source: Causaly
